The trajectory of companies tied to Viagra's history presents a challenging investment picture . While the initial boom generated substantial returns , generic alternatives have significantly diminished sales . Investing in related pharmaceutical firms now requires a discerning assessment of proprietary safeguards, evolving patient shifts , and the